Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Tips for Tomorrow: What 4 Experts Wish They Knew Earlier About ADCs

February 26th 2025

Clinicians with years of ADC therapy experience provide insights on the drug class and what is most important to keep in mind when treating patients.

Innovation in the Classroom

February 26th 2025

Faculty at Hackensack Meridian School of Medicine developed a novel curriculum to improve medical training through practical, clinic-focused learning.

Cardio-Oncology Investigations Begin to Uncover More Links Between CVD and Breast Cancer

February 26th 2025

For American Heart Month, cardiologist Amy M. Ahnert, MD, and oncologist Kevin T. Nead, MD, MPhil, unpacked the link between CVD and breast cancer.

Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer

February 25th 2025

Pedro Barata, MD, provides insights on key updates in RCC, MIBC, and prostate cancer, as discussed during a State of the Science Summit™.

OH2 Demonstrates Tolerability and Combination Activity in Advanced Sarcoma

February 25th 2025

OH2 monotherapy was safe and treatment with the agent led to responses in combination with HX008 in locally advanced or metastatic sarcoma.

Building the Next Generation of Oncology PAs

February 24th 2025

Noam E. Shabani, MS, PA-C, director of the Dana-Farber Postgraduate PA Oncology Fellowship highlights the program and its impact on improved access to care for patients.

Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC

February 21st 2025

Pivotal phase 3 trials are ongoing following data from a phase 1 study showing that adding mevrometostat to enzalutamide was safe and efficacious.

Immune Checkpoint Inhibitors Retain Their Role in the HCC Treatment Paradigm

February 19th 2025

Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.

Nadofaragene Firadenovec Trial Looks to Prove Efficacy in Intermediate-Risk NMIBC

February 19th 2025

Following its approval in high-risk BCG-unresponsive NMIBC with CIS, nadofaragene firadenovec is being assessed in intermediate-risk disease in ABLE-32.

The Heart of the Matter: Unraveling the Link Between CVD and Breast Cancer for American Heart Month

February 18th 2025

Amy M. Ahnert, MD, highlights newer shared risk factors for CVD and breast cancer and questions regarding personalized screening for the diseases.

A Cardiologist Highlights the Interwoven Elements of CVD and Breast Cancer

February 17th 2025

Amy M. Ahnert, MD, details the significance of findings on the link between CVD and breast cancer as well as next steps to further define the connection.

Investigators Look to Add Duvelisib to Treatment Arsenal of Rare T-Cell Lymphoma Subtype

February 17th 2025

Christopher P. Fox, PhD, discusses the upcoming phase 3 TERZO trial of duvelisib in patients with nodal T-cell lymphoma with follicular helper T phenotype.

Avutometinib/Defactinib Combo Could Fill Sizeable Unmet Need in LGSOC

February 17th 2025

Ritu Salani, MD, MBA, details the significance of trials examining avutometinib plus defactinib and enthusiasm for ADCs in ovarian cancer.

Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant

February 16th 2025

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies

February 16th 2025

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC

February 15th 2025

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies

February 15th 2025

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status

February 14th 2025

Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.

Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024

February 14th 2025

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC

February 14th 2025

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.